In the specific case of the application of TK inhibitors to the treatment of leukemia and lung cancer treatment as examples, diseases that target sequences have viral homologous, one important reason is that most patients (70–80%) respond to targeted therapy. The gene discussed is TKT; the disease is leukemia.